27 results
SC 14D9
PNT
POINT Biopharma Global Inc.
13 Oct 23
Tender offer solicitation
7:11am
of Lilly, visited POINT’s site in Toronto, Canada, during which representatives of Lilly and POINT toured the POINT Institute for Radioligand Innovation
SC TO-T
EX-99
PNT
POINT Biopharma Global Inc.
13 Oct 23
Third party tender offer statement
6:52am
of Lilly, visited POINT’s site in Toronto, Canada, during which representatives of Lilly and POINT toured the POINT Institute for Radioligand Innovation … Innovation.
Marschall S. Runge, M.D., Ph.D.*
Dr. Runge has served as a director of Lilly since 2013. Dr. Runge has served as executive vice president
SC14D9C
EX-99.7
PNT
POINT Biopharma Global Inc.
3 Oct 23
Written communication relating to third party tender offer
5:24pm
agreed to be acquired by Lilly. We are excited to see our pipeline benefit from Lilly’s commitment to oncology, its rich history of innovation and its deep
ARS
hs24n5i8
1 May 23
Annual report to shareholders
1:52pm
424B3
nmc5d 6gamb1dvovmdy2
11 Jul 22
Prospectus supplement
4:32pm
POS AM
4to14a1q9m8b
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
424B3
wfml1
31 Mar 22
Prospectus supplement
11:42am
POS AM
w8vdueyl
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
EX-99.1
vdy2vz 7wy
25 Feb 22
Prospectus supplement
8:39am
8-K
EX-99.1
j84swm
25 Feb 22
Regulation FD Disclosure
8:38am
8-K
EX-99.1
v9nb4 6fts
19 Nov 21
Regulation FD Disclosure
8:09am
424B3
oq3 k0iqgko3t
5 Aug 21
Prospectus supplement
4:26pm
S-4/A
EX-10.14
cj9lb5 h59i710mge1zr
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4
EX-10.14
w2q2cp7 l1ydh
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm
425
EX-99.1
8ui3pw gf
15 Mar 21
Business combination disclosure
8:20am
8-K
EX-99.1
0t148ir6
15 Mar 21
Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I
8:19am